1 |
16,5% cutaquig |
- |
- |
- |
- |
065 1件: 65 💬 |
2 |
36-482-hyaluronoglucosaminidase ph20 (rhuph20) |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 1件: 65 💬 |
3 |
[na] |
- |
- |
- |
- |
006 7件: 6 , 11, 35, 46, 53, 65, 299 💬 |
4 |
A10bk03 |
- |
- |
- |
- |
065 1件: 65 💬 |
5 |
Abatacept |
Abatacept |
1件: D03203 D03203 💬 |
CD80 2件: CD80, CD86 💬 |
Allograft rejection 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
6 |
Acoziborole (scyx-7158) |
SCYX-7158 |
- |
- |
- |
065 1件: 65 💬 |
7 |
Ada gene transfer |
- |
- |
- |
- |
065 1件: 65 💬 |
8 |
Ada pbsc |
- |
- |
- |
- |
065 1件: 65 💬 |
9 |
Ada umbilical cord blood cells |
- |
- |
- |
- |
065 1件: 65 💬 |
10 |
Adagen |
- |
- |
- |
- |
065 1件: 65 💬 |
11 |
Adenosine |
Adenosine |
1件: D00045 D00045 💬 |
ADORA1 4件: ADORA1, ADORA2A, ADORA2B, ADORA3 💬 |
Alcoholism 12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 3件: 13, 58, 65 💬 |
12 |
Administration of drug (interferon-gamma 1-b) subcutaneously |
- |
- |
- |
- |
065 1件: 65 💬 |
13 |
Adverse reactions of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
065 1件: 65 💬 |
14 |
Adverse reactions of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
065 1件: 65 💬 |
15 |
Adverse reactions of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
065 1件: 65 💬 |
16 |
Adverse reactions of gammagard subdermally at week 12 |
- |
- |
- |
- |
065 1件: 65 💬 |
17 |
Adverse reactions of gammagard subdermally at week 24 |
- |
- |
- |
- |
065 1件: 65 💬 |
18 |
Adverse reactions of gammagard subdermally at week 36 |
- |
- |
- |
- |
065 1件: 65 💬 |
19 |
Aldesleukin |
Aldesleukin |
1件: D00748 D00748 💬 |
IL2RA 3件: IL2RA, IL2RB, IL2RG 💬 |
Cytokine-cytokine receptor interaction 14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
049 4件: 49, 65, 96, 97 💬 |
20 |
Alefacept |
Alefacept |
1件: D02800 D02800 💬 |
CD58 1件: CD58 💬 |
Cell adhesion molecules 2件: Cell adhesion molecules, Epstein-Barr virus infection |
037 6件: 37, 60, 65, 164, 284, 285 💬 |
21 |
Alemtuzumab |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
013 16件: 13, 15, 19, 20, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬 |
22 |
Alemtuzumab 0.2 mg |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
065 2件: 65, 164 💬 |
23 |
Alemtuzumab 0.3 mg |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
065 2件: 65, 164 💬 |
24 |
Alentuzumab (campath) |
- |
- |
- |
- |
065 1件: 65 💬 |
25 |
Allogeneic peripheral blood stem cell |
- |
- |
- |
- |
065 1件: 65 💬 |
26 |
Anti-cd45 |
- |
- |
- |
- |
060 3件: 60, 65, 285 💬 |
27 |
Anti-thymocyte globulin |
- |
- |
- |
- |
011 18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 💬 |
28 |
Anti-thymocyte globulin (rabbit) |
Rabbit |
- |
- |
- |
060 4件: 60, 65, 96, 285 💬 |
29 |
Antithymocyte globulin |
- |
- |
- |
- |
060 3件: 60, 65, 284 💬 |
30 |
Aproart |
- |
- |
- |
- |
065 1件: 65 💬 |
31 |
Autologous cd34+ cell transduced with g2scid vector |
- |
- |
- |
- |
065 1件: 65 💬 |
32 |
Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
33 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
065 1件: 65 💬 |
34 |
Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with lentiviral vector that encodes for the human wiskott aldrich syndrome (was) cdna sequence |
- |
- |
- |
- |
065 1件: 65 💬 |
35 |
Autologous cd34+ hscs transduced ex vivo with efs lentiviral vector encoding for the human ada gene |
- |
- |
- |
- |
065 1件: 65 💬 |
36 |
Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
37 |
Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv) |
Adenosine |
1件: D00045 D00045 💬 |
ADORA1 4件: ADORA1, ADORA2A, ADORA2B, ADORA3 💬 |
Alcoholism 12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
065 1件: 65 💬 |
38 |
Azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
006 20件: 6 , 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
39 |
B-lymphocyte stimulator (blys) |
- |
- |
- |
- |
065 1件: 65 💬 |
40 |
Bacteriophage |
- |
- |
- |
- |
065 1件: 65 💬 |
41 |
Basiliximab |
Basiliximab |
1件: D03058 D03058 💬 |
IL2RA 1件: IL2RA 💬 |
Cytokine-cytokine receptor interaction 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 6件: 2 , 50, 65, 97, 222, 228 💬 |
42 |
Benznidazole |
Benznidazole |
1件: D02489 D02489 💬 |
- |
- |
065 1件: 65 💬 |
43 |
Biological sampling |
- |
- |
- |
- |
065 1件: 65 💬 |
44 |
Bivigam |
- |
- |
- |
- |
065 1件: 65 💬 |
45 |
Bms-188667 |
- |
- |
- |
- |
046 8件: 46, 49, 53, 65, 96, 97, 222, 271 💬 |
46 |
Bpx-501 t cells |
- |
- |
- |
- |
065 4件: 65, 284, 285, 326 💬 |
47 |
Bt090 |
- |
- |
- |
- |
065 1件: 65 💬 |
48 |
Bt524 |
- |
- |
- |
- |
065 1件: 65 💬 |
49 |
Bt595 |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
50 |
Bt681 |
- |
- |
- |
- |
065 1件: 65 💬 |
51 |
Busilvex |
- |
- |
- |
- |
019 4件: 19, 36, 60, 65 💬 |
52 |
Busilvex - 6 mg/ml - concentrato per soluzione per infusione - uso endovenoso - flaconcino - 10 ml 8 flaconcini |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
53 |
Busulfan |
Busulfan |
1件: D00248 D00248 💬 |
- |
- |
019 13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 💬 |
54 |
Busulfan iv |
Busulfan |
1件: D00248 D00248 💬 |
- |
- |
065 1件: 65 💬 |
55 |
Busulfan test dose |
Busulfan |
1件: D00248 D00248 💬 |
- |
- |
065 1件: 65 💬 |
56 |
Busulfan, cyclophosphamide, atg, gcsf |
Busulfan |
3件: D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
065 2件: 65, 284 💬 |
57 |
Busulfan, fludarabine and atg |
Busulfan |
3件: D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
58 |
Busulfan, fludarabine, atg, tli |
Busulfan |
3件: D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 2件: 65, 284 💬 |
59 |
C1 esterase inhibitor (human) |
- |
- |
- |
- |
065 1件: 65 💬 |
60 |
C1 esterase inhibitor human |
- |
- |
- |
- |
065 1件: 65 💬 |
61 |
C1 inhibitor |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
62 |
C1 inhibitor concentrate |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
63 |
C1-esterase inhibitor [recombinant] (c1-inh-r) |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
64 |
C1-inh |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
65 |
Campath |
- |
- |
- |
- |
019 12件: 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 💬 |
66 |
Campath -1h |
- |
- |
- |
- |
065 1件: 65 💬 |
67 |
Campath 1h |
- |
- |
- |
- |
060 4件: 60, 65, 164, 285 💬 |
68 |
Campath, fludarabine, cyclophosphamide |
Cyclophosphamide |
4件: D00287 D00287, D01907 D01907, D07760 D07760, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 2件: 65, 284 💬 |
69 |
Cd3/cd19 neg allogeneic bmt |
- |
- |
- |
- |
065 1件: 65 💬 |
70 |
Cd3/cd19 negative allogeneic hematopoietic stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
71 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
060 3件: 60, 65, 284 💬 |
72 |
Cd34+ |
- |
- |
- |
- |
065 1件: 65 💬 |
73 |
Cd34+ cells transduced with ada retrovir |
- |
- |
- |
- |
065 1件: 65 💬 |
74 |
Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt |
- |
- |
- |
- |
065 1件: 65 💬 |
75 |
Cd34+cells |
- |
- |
- |
- |
065 2件: 65, 285 💬 |
76 |
Cd45ra-depleted dli |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
77 |
Cdz173 |
- |
- |
- |
- |
053 2件: 53, 65 💬 |
78 |
Chloride |
Chloride ion |
- |
- |
- |
006 25件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
79 |
Cryopreserved efs-ada lv transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
80 |
Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
81 |
Cultured thymus tissue for implantation (ctti) |
- |
- |
- |
- |
065 1件: 65 💬 |
82 |
Cultured thymus tissue implantation (ctti) |
- |
- |
- |
- |
065 1件: 65 💬 |
83 |
Cutaquig |
- |
- |
- |
- |
065 1件: 65 💬 |
84 |
Cuvitru |
- |
- |
- |
- |
065 1件: 65 💬 |
85 |
Cuvitru 200 mg/ml solution for subcutaneous injection |
- |
- |
- |
- |
065 1件: 65 💬 |
86 |
Cyclophosphamide |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
011 44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 |
87 |
Cyclophosphamide (cytoxan) |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 1件: 65 💬 |
88 |
Cyclophosphamide 30 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 3件: 65, 285, 326 💬 |
89 |
Cyclophosphamide 40 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 3件: 65, 285, 326 💬 |
90 |
Cyclophosphamide dose level 1 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 2件: 65, 284 💬 |
91 |
Cyclophosphamide dose level 2 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 2件: 65, 284 💬 |
92 |
Cyclophosphamide dose level 3 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 2件: 65, 284 💬 |
93 |
Cyclophosphamide dose level 4 |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 2件: 65, 284 💬 |
94 |
Cyclophosphamide post transplant |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 1件: 65 💬 |
95 |
Cyclosporine |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 35件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
96 |
Cyclosporins |
- |
- |
- |
- |
053 4件: 53, 60, 65, 222 💬 |
97 |
Daclizumab |
Daclizumab |
1件: D03639 D03639 💬 |
IL2RA 1件: IL2RA 💬 |
Cytokine-cytokine receptor interaction 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 7件: 13, 56, 60, 65, 97, 283, 284 💬 |
98 |
Danazol |
Danazol |
1件: D00289 D00289 💬 |
AR 3件: AR, ESR1, PGR 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
060 5件: 60, 63, 64, 65, 285 💬 |
99 |
Data collection |
- |
- |
- |
- |
065 1件: 65 💬 |
100 |
Db289 |
- |
- |
- |
- |
065 1件: 65 💬 |
101 |
Depletion in cd45ra graft donor |
- |
- |
- |
- |
065 1件: 65 💬 |
102 |
Device: cell processing for tcrabeta+/cd19+ depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
103 |
Device: cell processing for tcraß+/cd19+ depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
104 |
Device: chrono super pid then generic syringe-gammanorm |
- |
- |
- |
- |
065 1件: 65 💬 |
105 |
Device: clinimacs |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
106 |
Device: clinimacs® cd34 reagent system cell sorter device |
- |
- |
- |
- |
065 1件: 65 💬 |
107 |
Device: continuous glucose monitor |
Dextrose, unspecified form |
- |
- |
- |
065 1件: 65 💬 |
108 |
Device: generic syringe then chrono super pid-gammanorm |
- |
- |
- |
- |
065 1件: 65 💬 |
109 |
Device: isolex 300i magnetic cell selector |
- |
- |
- |
- |
065 1件: 65 💬 |
110 |
Device: miltenyi clinimacs |
- |
- |
- |
- |
062 2件: 62, 65 💬 |
111 |
Device: miltenyi clinimacs selection system |
- |
- |
- |
- |
065 1件: 65 💬 |
112 |
Device: unrelated pbsc with t cell depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
113 |
Dexametasone fosfato sodico |
- |
- |
- |
- |
065 1件: 65 💬 |
114 |
Dexamethasone |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 162, 222, 235, 283, 296, 299 💬 |
115 |
Dexamethasone 21-dihydrogen phosphate |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
065 1件: 65 💬 |
116 |
Dexamethasone sodium phosphate |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
065 3件: 65, 70, 96 💬 |
117 |
Dexamethasone sodium phosphate ph. eur. |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
065 1件: 65 💬 |
118 |
Dextrose |
Dextrose, unspecified form |
- |
- |
- |
056 4件: 56, 60, 65, 70 💬 |
119 |
Dextrose, 5% in water |
Dextrose, unspecified form |
1件: D00001 D00001 💬 |
- |
- |
065 1件: 65 💬 |
120 |
Diagnostic test: blood drawing in healthy controls |
- |
- |
- |
- |
065 1件: 65 💬 |
121 |
Diagnostic test: blood drawing in patients with was |
- |
- |
- |
- |
065 1件: 65 💬 |
122 |
Diagnostic test: functional and antigenic c1 inhibitor |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
123 |
Diagnostic test: oral glucose tolerance test |
Dextrose, unspecified form |
- |
- |
- |
013 3件: 13, 65, 299 💬 |
124 |
Diagnostic test: rna and neopterin detection |
Neopterin |
- |
- |
- |
065 1件: 65 💬 |
125 |
Donor peripheral blood stem cells. |
- |
- |
- |
- |
065 1件: 65 💬 |
126 |
Ef1as-ada lentiviral vector gene modified autologous cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
127 |
Ef1as-ada lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
128 |
Efficacy of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
065 1件: 65 💬 |
129 |
Efficacy of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
065 1件: 65 💬 |
130 |
Efficacy of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
065 1件: 65 💬 |
131 |
Efficacy of gammagard subdermally at week 12 |
- |
- |
- |
- |
065 1件: 65 💬 |
132 |
Efficacy of gammagard subdermally at week 24 |
- |
- |
- |
- |
065 1件: 65 💬 |
133 |
Efficacy of gammagard subdermally at week 36 |
- |
- |
- |
- |
065 1件: 65 💬 |
134 |
Eflornithine |
Eflornithine |
1件: D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
135 |
Eflornithine plus nifurtimox combination therapy |
Eflornithine |
2件: D00833 D00833, D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
136 |
Elapegademase |
Elapegademase |
1件: D11017 D11017 💬 |
ADA 1件: ADA 💬 |
Metabolic pathways 3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism |
065 1件: 65 💬 |
137 |
Elapegademase-lvlr |
Elapegademase |
1件: D11017 D11017 💬 |
ADA 1件: ADA 💬 |
Metabolic pathways 3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism |
065 1件: 65 💬 |
138 |
Eltrombopag |
Eltrombopag |
1件: D03978 D03978 💬 |
- |
- |
060 5件: 60, 63, 65, 284, 285 💬 |
139 |
Empagliflozin |
Empagliflozin |
1件: D10459 D10459 💬 |
- |
- |
065 3件: 65, 72, 257 💬 |
140 |
Ep2006 |
- |
- |
- |
- |
065 1件: 65 💬 |
141 |
Ep2006 (filgrastim) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
142 |
Etoposide |
Etoposide |
2件: D00125 D00125, D04107 D04107 💬 |
TOP2A 2件: TOP2A, TOP2B 💬 |
Platinum drug resistance 1件: Platinum drug resistance |
011 11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬 |
143 |
Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector |
- |
- |
- |
- |
065 1件: 65 💬 |
144 |
Ezn-2279 |
- |
- |
- |
- |
065 1件: 65 💬 |
145 |
Fansidar (pyrimethamine and sulfadoxine) |
Pyrimethamine |
2件: D00488 D00488, D00580 D00580 💬 |
- |
- |
065 1件: 65 💬 |
146 |
Fexinidazole |
Fexinidazole |
1件: D11252 D11252 💬 |
- |
- |
065 1件: 65 💬 |
147 |
Fibrinogen |
Fibrinogen human |
- |
- |
- |
014 3件: 14, 65, 288 💬 |
148 |
Fibrinogen (coagulation factori) |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
149 |
Fibrinogen concentrate from human plasma |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
150 |
Filgrastim |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 27件: 2 , 6 , 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 |
151 |
Filgrastim hexal |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
152 |
Filgrastim, alemtuzumab |
Alemtuzumab |
2件: D02802 D02802, D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
153 |
Flebogamma 5% dif |
- |
- |
- |
- |
065 1件: 65 💬 |
154 |
Fludarabina |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 2件: 19, 65 💬 |
155 |
Fludarabina accord |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
156 |
Fludarabina teva - 25 mg/ml concentrato per soluzione iniettabile o per infusione 1 flaconcino di vetro da 2 ml |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
157 |
Fludarabine |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 💬 |
158 |
Fludarabine monophosphate |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 3件: 65, 284, 326 💬 |
159 |
Fludarabine phosphate |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
028 11件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 💬 |
160 |
Fludarabine phosphate 30 mg |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 2件: 65, 164 💬 |
161 |
Fludarabine phosphate 40 mg |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 2件: 65, 164 💬 |
162 |
Fludarabine, busulfan, thymoglobulin |
Antithymocyte immunoglobulin (rabbit) |
3件: D00248 D00248, D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
163 |
Fludarabine, melphalan, thiotepa |
Fludarabine |
4件: D00369 D00369, D00583 D00583, D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
164 |
Fortecortin |
- |
- |
- |
- |
028 2件: 28, 65 💬 |
165 |
Fortecortin inject 40 mg amp. |
- |
- |
- |
- |
065 1件: 65 💬 |
166 |
Fucose |
Fucose |
- |
- |
- |
065 1件: 65 💬 |
167 |
G-csf |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 16件: 2 , 6 , 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 💬 |
168 |
G-csf for conditioning before hsct. |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
169 |
G1xcg |
- |
- |
- |
- |
065 1件: 65 💬 |
170 |
G1xcgd transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
171 |
Gadolinium |
Gadolinium |
- |
- |
- |
013 6件: 13, 34, 46, 58, 65, 86 💬 |
172 |
Gadolinium for abdomen |
Gadolinium |
- |
- |
- |
065 1件: 65 💬 |
173 |
Gadolinium for lower back |
Gadolinium |
- |
- |
- |
065 1件: 65 💬 |
174 |
Gammagard liquid |
- |
- |
- |
- |
065 1件: 65 💬 |
175 |
Gammagard s/d (solvent/detergent) |
- |
- |
- |
- |
065 1件: 65 💬 |
176 |
Gammaglobulin |
- |
- |
- |
- |
065 1件: 65 💬 |
177 |
Gammanorm |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
178 |
Gammanorm 165 mg/ml |
- |
- |
- |
- |
065 1件: 65 💬 |
179 |
Gammaplex |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
180 |
Gammaplex (5%) |
- |
- |
- |
- |
065 1件: 65 💬 |
181 |
Gammaplex (intravenous immunoglobulin) |
- |
- |
- |
- |
065 1件: 65 💬 |
182 |
Gammaplex 10 |
- |
- |
- |
- |
065 1件: 65 💬 |
183 |
Gamunex-c |
- |
- |
- |
- |
065 1件: 65 💬 |
184 |
Gcsf |
- |
- |
- |
- |
065 1件: 65 💬 |
185 |
Gene therapy method for cgd |
- |
- |
- |
- |
065 1件: 65 💬 |
186 |
Gene transfer |
- |
- |
- |
- |
065 1件: 65 💬 |
187 |
Gene-transduced autologous cd34+ stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
188 |
Genetic: cl20-i4-ef1a-h?c-opt |
- |
- |
- |
- |
065 1件: 65 💬 |
189 |
Genetic: infusion of autologous cryopreserved efs-ada lv cd34+ cells (otl-101) |
- |
- |
- |
- |
065 1件: 65 💬 |
190 |
Genetic: infusion of autologous efs-ada lv cd34+ (otl-101) |
- |
- |
- |
- |
065 1件: 65 💬 |
191 |
Genetic: infusion of autologous efs-ada lv cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
192 |
Genetically modified autologous blood stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
193 |
Glucose |
Dextrose, unspecified form |
- |
- |
- |
002 15件: 2 , 6 , 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
194 |
Glycolic acid |
Glycolic acid |
- |
- |
- |
065 1件: 65 💬 |
195 |
Glycosade |
- |
- |
- |
- |
065 3件: 65, 256, 257 💬 |
196 |
Gold |
Gold |
- |
- |
- |
002 38件: 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
197 |
Granulocyte colony stimulating factor |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 6件: 2 , 28, 36, 57, 65, 85 💬 |
198 |
Granulocyte colony stimulating factor (g-csf) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
199 |
Gtg003.08 |
- |
- |
- |
- |
065 1件: 65 💬 |
200 |
Gvhd prophylaxis |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
201 |
Haemocomplettan p |
- |
- |
- |
- |
065 1件: 65 💬 |
202 |
Haemocomplettan(r) p |
- |
- |
- |
- |
065 1件: 65 💬 |
203 |
Haemocomplettan(r) p 1g/2g |
- |
- |
- |
- |
065 1件: 65 💬 |
204 |
Haplo bm with t cell depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
205 |
Haploidentical hematopoietic cell transplantation |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
206 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
019 5件: 19, 65, 120, 160, 326 💬 |
207 |
Hematopoietic stem cell transplant |
- |
- |
- |
- |
065 1件: 65 💬 |
208 |
Hizentra |
- |
- |
- |
- |
014 4件: 14, 50, 51, 65 💬 |
209 |
Hizentra® |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
210 |
Horse -anti-thymocyte |
- |
- |
- |
- |
065 1件: 65 💬 |
211 |
Hpc, a infusion |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
212 |
Htlp |
- |
- |
- |
- |
065 1件: 65 💬 |
213 |
Human fibrinogen |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
214 |
Human fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
215 |
Human immunglobulin g (igg) |
- |
- |
- |
- |
065 1件: 65 💬 |
216 |
Human immunoglobulin |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
217 |
Human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
014 4件: 14, 50, 63, 65 💬 |
218 |
Human normal immunoglobulin |
Human immunoglobulin G |
- |
- |
- |
011 9件: 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
219 |
Human normal immunoglobulin (iv) |
Human immunoglobulin G |
- |
- |
- |
011 4件: 11, 14, 63, 65 💬 |
220 |
Human normal immunoglobulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 2件: 50, 65 💬 |
221 |
Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
222 |
Human normal immunoglobulin (subcutaneous) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
223 |
Human normal immunoglobulin for |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
224 |
Human normal immunoglobulin for intravenous administration |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 51, 65 💬 |
225 |
Human normal immunoglobulin for intravenous use |
Human immunoglobulin G |
- |
- |
- |
063 2件: 63, 65 💬 |
226 |
Human normal immunoglobulin for intravenous use (ivig) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
227 |
Human normal immunoglobulin for subcutaneous administration |
Human immunoglobulin G |
- |
- |
- |
051 2件: 51, 65 💬 |
228 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
229 |
Human normal immunoglobulin g (igg > 98% purity) |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 63, 65 💬 |
230 |
Hyaluronidase |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
028 4件: 28, 51, 65, 331 💬 |
231 |
Hyaluronoglucosaminidase |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 1件: 65 💬 |
232 |
Hydroxyurea |
Hydroxyurea |
1件: D00341 D00341 💬 |
RRM2 1件: RRM2 💬 |
Drug metabolism - other enzymes 6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
003 8件: 3 , 13, 19, 20, 65, 85, 86, 284 💬 |
233 |
Hyqvia |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
234 |
Hyqvia 100 mg/ml solution for infusion for subcutaneous use |
- |
- |
- |
- |
065 1件: 65 💬 |
235 |
I10e |
- |
- |
- |
- |
014 3件: 14, 63, 65 💬 |
236 |
Ibuprofen |
Ibuprofen |
4件: D00126 D00126, D01122 D01122, D04490 D04490, D06606 D06606 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
013 6件: 13, 46, 65, 113, 271, 299 💬 |
237 |
Ifn-gamma |
- |
- |
- |
- |
065 1件: 65 💬 |
238 |
Ig vena 50 g/l solution for infusion 100 ml vial + infusion set |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
239 |
Igg next generation |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
240 |
Ighy10 |
- |
- |
- |
- |
065 1件: 65 💬 |
241 |
Igiv, 10% |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
242 |
Igiv-c 10% |
- |
- |
- |
- |
065 1件: 65 💬 |
243 |
Ignextgen 16% |
- |
- |
- |
- |
065 1件: 65 💬 |
244 |
Igng |
- |
- |
- |
- |
065 1件: 65 💬 |
245 |
Igpro10 |
- |
- |
- |
- |
014 3件: 14, 51, 65 💬 |
246 |
Igpro20 |
- |
- |
- |
- |
014 4件: 14, 50, 51, 65 💬 |
247 |
Igsc 20% |
- |
- |
- |
- |
065 1件: 65 💬 |
248 |
Igsc 20% 150 mg/kg |
- |
- |
- |
- |
065 1件: 65 💬 |
249 |
Igsc 20% daily push versus 2 times per week pump |
- |
- |
- |
- |
065 1件: 65 💬 |
250 |
Igsc 20% daily push versus every 2 weeks pump |
- |
- |
- |
- |
065 1件: 65 💬 |
251 |
Igsc 20% daily push versus once a week pump |
- |
- |
- |
- |
065 1件: 65 💬 |
252 |
Igsc, 16% |
- |
- |
- |
- |
065 1件: 65 💬 |
253 |
Igsc, 20% |
- |
- |
- |
- |
065 1件: 65 💬 |
254 |
Immune globulin infusion (human), 10% |
- |
- |
- |
- |
065 1件: 65 💬 |
255 |
Immune globulin intravenous |
- |
- |
- |
- |
065 1件: 65 💬 |
256 |
Immune globulin intravenous (human) |
- |
- |
- |
- |
065 1件: 65 💬 |
257 |
Immune globulin intravenous (human) 5% liquid, ivig-sn™ |
- |
- |
- |
- |
065 1件: 65 💬 |
258 |
Immune globulin intravenous (human), 10% |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
259 |
Immune globulin intravenous (human), 10% solution |
- |
- |
- |
- |
065 1件: 65 💬 |
260 |
Immune globulin intravenous (human), 10% tvr (triple virally reduced) solution |
- |
- |
- |
- |
065 1件: 65 💬 |
261 |
Immune globulin intravenous (igiv) |
- |
- |
- |
- |
065 1件: 65 💬 |
262 |
Immune globulin intravenous [human], 10% caprylate/chromatography purified |
- |
- |
- |
- |
065 1件: 65 💬 |
263 |
Immune globulin subcutaneos, 20% |
- |
- |
- |
- |
065 1件: 65 💬 |
264 |
Immune globulin subcutaneous (human) |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
265 |
Immune globulin subcutaneous (human) (scig) |
- |
- |
- |
- |
065 1件: 65 💬 |
266 |
Immune globulin subcutaneous (human), 20% |
- |
- |
- |
- |
065 1件: 65 💬 |
267 |
Immune globulin subcutaneous (human), 20% caprylate/chromatography purified (igsc 20%) |
- |
- |
- |
- |
065 1件: 65 💬 |
268 |
Immune globulin subcutaneous (human), 20% solution |
- |
- |
- |
- |
065 1件: 65 💬 |
269 |
Immune globulin subcutaneous (human), 20%, caprylate/chromatography purified |
- |
- |
- |
- |
065 1件: 65 💬 |
270 |
Immune globulin subcutaneous, 20% |
- |
- |
- |
- |
065 1件: 65 💬 |
271 |
Immune globulin subcutaneous, 20% solution (igsc, 20%) |
- |
- |
- |
- |
065 1件: 65 💬 |
272 |
Immunglobulin (human) |
- |
- |
- |
- |
065 1件: 65 💬 |
273 |
Immunoglobulin g |
- |
- |
- |
- |
011 7件: 11, 13, 14, 49, 50, 63, 65 💬 |
274 |
Immunoglobulin g (ig nextgen 16%) |
- |
- |
- |
- |
065 1件: 65 💬 |
275 |
Immunoglobulin intravenous (human) |
- |
- |
- |
- |
065 1件: 65 💬 |
276 |
Immunoglobulins intravenous (human) |
- |
- |
- |
- |
065 1件: 65 💬 |
277 |
Immunoglobulins, normal human |
- |
- |
- |
- |
065 1件: 65 💬 |
278 |
Immunological diagnosis tests |
- |
- |
- |
- |
065 1件: 65 💬 |
279 |
Immunosuppression only conditioning (ioc) |
- |
- |
- |
- |
065 1件: 65 💬 |
280 |
Immunosuppression only conditioning - closed with amendment l |
- |
- |
- |
- |
065 1件: 65 💬 |
281 |
Increlex |
- |
- |
- |
- |
065 4件: 65, 78, 96, 299 💬 |
282 |
Infliximab |
Infliximab |
1件: D02598 D02598 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
035 24件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 💬 |
283 |
Inh |
- |
- |
- |
- |
065 1件: 65 💬 |
284 |
Interferon gamma |
Interferon Gamma |
- |
- |
- |
018 8件: 18, 65, 85, 107, 228, 299, 301, 326 💬 |
285 |
Interferon gamma-1b |
Interferon Gamma |
1件: D00747 D00747 💬 |
IFNGR1 2件: IFNGR1, IFNGR2 💬 |
Chagas disease 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
018 7件: 18, 65, 85, 228, 299, 301, 326 💬 |
286 |
Interferon-gamma |
- |
- |
- |
- |
065 1件: 65 💬 |
287 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
002 8件: 2 , 35, 49, 55, 65, 96, 97, 162 💬 |
288 |
Intratect |
- |
- |
- |
- |
013 3件: 13, 35, 65 💬 |
289 |
Intravenous immunoglobulin infusion |
- |
- |
- |
- |
065 1件: 65 💬 |
290 |
Intravenous infusion of transduced cells |
- |
- |
- |
- |
065 1件: 65 💬 |
291 |
Itraconazole |
Itraconazole |
1件: D00350 D00350 💬 |
- |
- |
003 4件: 3 , 65, 227, 299 💬 |
292 |
Iv treatment with igsc, 10% |
- |
- |
- |
- |
065 1件: 65 💬 |
293 |
Ivig |
Human immunoglobulin G |
- |
- |
- |
011 8件: 11, 13, 14, 17, 35, 50, 51, 65 💬 |
294 |
Ivig-peg |
- |
- |
- |
- |
065 1件: 65 💬 |
295 |
Jardiance |
- |
- |
- |
- |
065 1件: 65 💬 |
296 |
Kedrion ivig 10% |
- |
- |
- |
- |
065 1件: 65 💬 |
297 |
Kig10 |
- |
- |
- |
- |
065 1件: 65 💬 |
298 |
Kineret |
- |
- |
- |
- |
028 9件: 28, 41, 46, 49, 65, 106, 107, 266, 299 💬 |
299 |
Kiovig |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
300 |
Kiovig 100 mg/ml solution for infusion |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
301 |
Klh |
- |
- |
- |
- |
013 2件: 13, 65 💬 |
302 |
Kvd900 |
- |
- |
- |
- |
065 1件: 65 💬 |
303 |
Kvd900 100 mg film coated tablet |
- |
- |
- |
- |
065 1件: 65 💬 |
304 |
L-fucose |
Fucose |
- |
- |
- |
065 1件: 65 💬 |
305 |
Ladicell |
- |
- |
- |
- |
065 1件: 65 💬 |
306 |
Ldt |
- |
- |
- |
- |
065 1件: 65 💬 |
307 |
Lemtrada |
- |
- |
- |
- |
013 2件: 13, 65 💬 |
308 |
Leniolisib |
Leniolisib |
1件: D11158 D11158 💬 |
PIK3CA 3件: PIK3CA, PIK3CB, PIK3CD 💬 |
AGE-RAGE signaling pathway in diabetic complications 103件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway |
053 2件: 53, 65 💬 |
309 |
Lenograstim |
Lenograstim |
1件: D03247 D03247 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 7件: 2 , 13, 16, 18, 19, 57, 65 💬 |
310 |
Lentiviral g1xcgd gene therapy |
- |
- |
- |
- |
065 1件: 65 💬 |
311 |
Lentiviral vector transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
312 |
Lfb-igsc |
- |
- |
- |
- |
065 1件: 65 💬 |
313 |
Mabthera |
- |
- |
- |
- |
011 22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬 |
314 |
Mabthera - 2 fiale 100 mg 10 ml |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
315 |
Mavorixafor |
- |
- |
- |
- |
065 1件: 65 💬 |
316 |
Mctls |
- |
- |
- |
- |
065 1件: 65 💬 |
317 |
Melarsoprol |
Melarsoprol |
1件: D00832 D00832 💬 |
- |
- |
065 1件: 65 💬 |
318 |
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d |
Eflornithine |
2件: D00832 D00832, D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
319 |
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d |
Melarsoprol |
2件: D00832 D00832, D00833 D00833 💬 |
- |
- |
065 1件: 65 💬 |
320 |
Melphalan |
Melphalan |
1件: D00369 D00369 💬 |
- |
- |
011 15件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬 |
321 |
Mesna |
- |
- |
- |
- |
011 11件: 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164 💬 |
322 |
Methotrexate |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
323 |
Methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
324 |
Methylprednisolone or prednisolone |
Methylprednisolone |
14件: D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
065 1件: 65 💬 |
325 |
Mmf |
- |
- |
- |
- |
013 13件: 13, 35, 40, 49, 50, 51, 60, 65, 66, 222, 224, 226, 299 💬 |
326 |
Monitor |
Methamidophos |
- |
- |
- |
002 18件: 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
327 |
Mozobil |
- |
- |
- |
- |
019 3件: 19, 65, 285 💬 |
328 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - flaconcino (vetro) - 24 mg/1.2 ml 1 flaconcino |
- |
- |
- |
- |
065 1件: 65 💬 |
329 |
Mozobil 20mg/ml vial (injectable solution for subcutaneous use) |
- |
- |
- |
- |
065 1件: 65 💬 |
330 |
Mozobil 20mg/ml vial (injectable solution, subcutaneous use) |
- |
- |
- |
- |
065 1件: 65 💬 |
331 |
Mozobil, |
- |
- |
- |
- |
065 1件: 65 💬 |
332 |
Mycophenolate |
Mycophenolic acid |
1件: D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 34件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
333 |
Mycophenolate mofetil |
Mycophenolate mofetil |
4件: D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 32件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
334 |
Mycophenolate mofetil (mmf) |
Mycophenolate mofetil |
4件: D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
013 7件: 13, 49, 51, 60, 65, 66, 222 💬 |
335 |
Myeloablative conditioning-closed with amendment l |
- |
- |
- |
- |
065 1件: 65 💬 |
336 |
Myeloablative preparative regimen |
- |
- |
- |
- |
062 3件: 62, 65, 284 💬 |
337 |
Myelostim |
- |
- |
- |
- |
065 1件: 65 💬 |
338 |
Myelostim - 34 1 flaconcino liofilizzato 33.6 miu + siringa preriempita solvente 1 ml |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
339 |
Myelostim 34 milions ui/ml - powder and solvent for solution for injection/infusion |
- |
- |
- |
- |
065 1件: 65 💬 |
340 |
Myelostim 34 milions ui/ml, powder and solvent for solution for injection or infusion |
- |
- |
- |
- |
065 1件: 65 💬 |
341 |
Nanogam 100 mg/ml |
- |
- |
- |
- |
065 1件: 65 💬 |
342 |
Nanogam® 50 mg/ml |
- |
- |
- |
- |
065 1件: 65 💬 |
343 |
Ndv-3a |
- |
- |
- |
- |
065 1件: 65 💬 |
344 |
Neopterin |
Neopterin |
- |
- |
- |
065 1件: 65 💬 |
345 |
Newgam |
- |
- |
- |
- |
014 3件: 14, 63, 65 💬 |
346 |
Newnorm |
- |
- |
- |
- |
065 1件: 65 💬 |
347 |
Nifurtimox |
Nifurtimox |
1件: D00833 D00833 💬 |
- |
- |
065 1件: 65 💬 |
348 |
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d |
Eflornithine |
2件: D00833 D00833, D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
349 |
Nifurtimox-eflronithine combination treatment (nect) |
Nifurtimox |
1件: D00833 D00833 💬 |
- |
- |
065 1件: 65 💬 |
350 |
None |
- |
- |
- |
- |
046 14件: 46, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299 💬 |
351 |
Normal human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
352 |
Noxafil |
- |
- |
- |
- |
060 3件: 60, 65, 299 💬 |
353 |
Noxafil 40 mg/ml oral solution |
- |
- |
- |
- |
065 1件: 65 💬 |
354 |
Octa-c1-inh |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
355 |
Octagam |
- |
- |
- |
- |
013 2件: 13, 65 💬 |
356 |
Octagam 10% |
- |
- |
- |
- |
050 3件: 50, 63, 65 💬 |
357 |
Octagam 5% |
- |
- |
- |
- |
013 2件: 13, 65 💬 |
358 |
Octagam 50 mg/ml oldatos infúzió |
- |
- |
- |
- |
065 1件: 65 💬 |
359 |
Octanorm |
- |
- |
- |
- |
050 2件: 50, 65 💬 |
360 |
Octanorm 16.5% |
- |
- |
- |
- |
050 2件: 50, 65 💬 |
361 |
Omalizumab |
Omalizumab |
1件: D05251 D05251 💬 |
FCER1A 1件: FCER1A 💬 |
Asthma 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 7件: 46, 53, 65, 98, 162, 226, 299 💬 |
362 |
Omalizumab (xolair) |
Omalizumab |
1件: D05251 D05251 💬 |
FCER1A 1件: FCER1A 💬 |
Asthma 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
065 1件: 65 💬 |
363 |
Orencia |
- |
- |
- |
- |
044 13件: 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 160, 222, 271 💬 |
364 |
Orencia® 125 mg solution for injection in pre-filled syringe |
- |
- |
- |
- |
065 1件: 65 💬 |
365 |
Other hematological agents |
- |
- |
- |
- |
065 1件: 65 💬 |
366 |
Other: |
- |
- |
- |
- |
002 2件: 2 , 65 💬 |
367 |
Other: 0.9% sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
065 1件: 65 💬 |
368 |
Other: blood sampling for laboratory developed test (ldt) analysis |
- |
- |
- |
- |
065 1件: 65 💬 |
369 |
Other: cultured thymus tissue implantation and parental parathyroid transplantation |
- |
- |
- |
- |
065 1件: 65 💬 |
370 |
Other: cultured thymus tissue implantation with parathyroid transplantation |
- |
- |
- |
- |
065 1件: 65 💬 |
371 |
Other: donor lymphocyte infusion |
- |
- |
- |
- |
065 1件: 65 💬 |
372 |
Other: food diary |
- |
- |
- |
- |
065 1件: 65 💬 |
373 |
Other: haematopoietic stem cell transplantation (hsct) |
- |
- |
- |
- |
065 1件: 65 💬 |
374 |
Other: laboratory biomarker analysis |
- |
- |
- |
- |
011 21件: 11, 13, 14, 16, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 232, 283, 284, 285, 298, 331 💬 |
375 |
Other: medical history questionnaires |
- |
- |
- |
- |
065 1件: 65 💬 |
376 |
Other: modified mixed meal tolerance test |
- |
- |
- |
- |
065 1件: 65 💬 |
377 |
Other: modified oral glucose tolerance test |
Dextrose, unspecified form |
- |
- |
- |
065 1件: 65 💬 |
378 |
Other: palliative care |
- |
- |
- |
- |
019 5件: 19, 65, 120, 160, 326 💬 |
379 |
Otl-101 |
- |
- |
- |
- |
065 1件: 65 💬 |
380 |
Otl-103 |
- |
- |
- |
- |
065 1件: 65 💬 |
381 |
Otl-103 dispersion for infusion |
- |
- |
- |
- |
065 1件: 65 💬 |
382 |
Ovastat |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
013 2件: 13, 65 💬 |
383 |
Ovastat 1000 |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
013 2件: 13, 65 💬 |
384 |
Ovastat 1000 (treosulfan injection) |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
065 1件: 65 💬 |
385 |
Ovastat 1000 mg, powder for solution for infusion |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
065 1件: 65 💬 |
386 |
Ovastat 5000 |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
013 2件: 13, 65 💬 |
387 |
Ovastat 5000 (treosulfan injection) |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
065 1件: 65 💬 |
388 |
Ovastat 5000 mg, powder for solution for infusion |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
065 1件: 65 💬 |
389 |
Palifermin |
Palifermin |
1件: D05338 D05338 💬 |
FGFR2 1件: FGFR2 💬 |
Calcium signaling pathway 13件: Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
013 4件: 13, 38, 39, 65 💬 |
390 |
Pantoprazole |
Pantoprazole |
2件: D02593 D02593, D05353 D05353 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
013 2件: 13, 65 💬 |
391 |
Pantoprazolo 20 mg gastro-resistant tablets |
- |
- |
- |
- |
065 1件: 65 💬 |
392 |
Peg |
- |
- |
- |
- |
006 9件: 6 , 13, 46, 65, 78, 96, 97, 240, 299 💬 |
393 |
Peg-ada |
- |
- |
- |
- |
065 1件: 65 💬 |
394 |
Peg-ada ert |
- |
- |
- |
- |
065 1件: 65 💬 |
395 |
Peg-interleukin-2 |
Human interleukin-2 |
- |
- |
- |
065 1件: 65 💬 |
396 |
Pentamidine |
Pentamidine |
2件: D00834 D00834, D08333 D08333 💬 |
- |
- |
065 1件: 65 💬 |
397 |
Peripheral blood stem cells |
- |
- |
- |
- |
051 2件: 51, 65 💬 |
398 |
Pha-022121 |
- |
- |
- |
- |
065 1件: 65 💬 |
399 |
Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
400 |
Phosphate |
Phosphate ion |
- |
- |
- |
002 30件: 2 , 3 , 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 276, 283, 284, 285, 286, 299 💬 |
401 |
Pid |
- |
- |
- |
- |
065 1件: 65 💬 |
402 |
Pioglitazone |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 17件: 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
403 |
Plerixafor |
Plerixafor |
1件: D08971 D08971 💬 |
CXCR4 1件: CXCR4 💬 |
Axon guidance 12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
020 5件: 20, 51, 65, 285, 299 💬 |
404 |
Plerixafor for conditioning before hsct. |
Plerixafor |
1件: D08971 D08971 💬 |
CXCR4 1件: CXCR4 💬 |
Axon guidance 12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
065 1件: 65 💬 |
405 |
Pncj pps |
- |
- |
- |
- |
065 1件: 65 💬 |
406 |
Pneumo 23 |
- |
- |
- |
- |
065 1件: 65 💬 |
407 |
Polyclonal igg |
- |
- |
- |
- |
065 1件: 65 💬 |
408 |
Posaconazole |
Posaconazole |
1件: D02555 D02555 💬 |
- |
- |
060 3件: 60, 65, 299 💬 |
409 |
Posaconazole (psz) |
Posaconazole |
1件: D02555 D02555 💬 |
- |
- |
065 1件: 65 💬 |
410 |
Pps |
- |
- |
- |
- |
065 1件: 65 💬 |
411 |
Prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
011 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
412 |
Prednisone |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
413 |
Prevenar |
- |
- |
- |
- |
065 1件: 65 💬 |
414 |
Privigen |
- |
- |
- |
- |
011 4件: 11, 14, 51, 65 💬 |
415 |
Privigen® |
- |
- |
- |
- |
014 3件: 14, 63, 65 💬 |
416 |
Procedure: allo bmt |
- |
- |
- |
- |
065 1件: 65 💬 |
417 |
Procedure: allogeneic bone marrow transplantation |
- |
- |
- |
- |
060 6件: 60, 65, 96, 164, 284, 285 💬 |
418 |
Procedure: allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 8件: 28, 51, 60, 62, 65, 164, 284, 285 💬 |
419 |
Procedure: allogeneic hsc |
- |
- |
- |
- |
065 1件: 65 💬 |
420 |
Procedure: allogeneic hsct |
- |
- |
- |
- |
065 1件: 65 💬 |
421 |
Procedure: blood draw |
- |
- |
- |
- |
006 5件: 6 , 19, 65, 231, 299 💬 |
422 |
Procedure: blood sample |
- |
- |
- |
- |
065 1件: 65 💬 |
423 |
Procedure: ct scan |
- |
- |
- |
- |
065 1件: 65 💬 |
424 |
Procedure: cyclophosphamide |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
065 1件: 65 💬 |
425 |
Procedure: hematopoietic stem cell transplantation |
- |
- |
- |
- |
013 3件: 13, 65, 285 💬 |
426 |
Procedure: in vitro-treated peripheral blood stem cell transplantation |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
427 |
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 6件: 28, 51, 60, 62, 65, 285 💬 |
428 |
Procedure: peripheral blood stem cell transplantation |
- |
- |
- |
- |
011 11件: 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285 💬 |
429 |
Procedure: stem cell infusion |
- |
- |
- |
- |
028 5件: 28, 60, 65, 284, 285 💬 |
430 |
Procedure: stem cell transplant |
- |
- |
- |
- |
019 5件: 19, 20, 65, 164, 284 💬 |
431 |
Procedure: stem cell transplantation |
- |
- |
- |
- |
019 6件: 19, 51, 60, 62, 65, 326 💬 |
432 |
Procedure: total body irradiation |
- |
- |
- |
- |
019 6件: 19, 20, 51, 60, 65, 285 💬 |
433 |
Procedure: total lymphoid irradiation |
- |
- |
- |
- |
065 3件: 65, 284, 326 💬 |
434 |
Procedure: umbilical cord blood transplantation |
- |
- |
- |
- |
060 5件: 60, 65, 284, 285, 326 💬 |
435 |
Proleukin |
- |
- |
- |
- |
002 3件: 2 , 49, 65 💬 |
436 |
Proleukin® s |
- |
- |
- |
- |
065 1件: 65 💬 |
437 |
Promacta |
- |
- |
- |
- |
063 2件: 63, 65 💬 |
438 |
Prometic's immune globulin intravenous 10% |
- |
- |
- |
- |
065 1件: 65 💬 |
439 |
Psrs11.efs.il2rg.pre* retroviral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
440 |
Psrs11.efs.il2rg.pre* retroviral vector transduce |
- |
- |
- |
- |
065 1件: 65 💬 |
441 |
Psrs11.efs.il2rg.pre* retroviral vector transduced cells |
- |
- |
- |
- |
065 1件: 65 💬 |
442 |
Pth |
- |
- |
- |
- |
065 2件: 65, 235 💬 |
443 |
Pth 1-34 |
Teriparatide |
1件: D06078 D06078 💬 |
PTH1R 1件: PTH1R 💬 |
Endocrine and other factor-regulated calcium reabsorption 3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
065 2件: 65, 235 💬 |
444 |
Purified vero cell vaccine) |
- |
- |
- |
- |
065 1件: 65 💬 |
445 |
Pyrimethamine |
Pyrimethamine |
1件: D00488 D00488 💬 |
- |
- |
002 4件: 2 , 4 , 19, 65 💬 |
446 |
R-hil-18bp |
- |
- |
- |
- |
065 1件: 65 💬 |
447 |
Rabbit |
Rabbit |
- |
- |
- |
011 8件: 11, 13, 49, 51, 60, 65, 96, 285 💬 |
448 |
Rabbit anti-thymocyte globulin |
Rabbit |
- |
- |
- |
049 2件: 49, 65 💬 |
449 |
Radiation: radiation therapy |
- |
- |
- |
- |
034 5件: 34, 60, 65, 284, 285 💬 |
450 |
Radiation: total body 200cgy |
- |
- |
- |
- |
065 1件: 65 💬 |
451 |
Radiation: total body irradiation |
- |
- |
- |
- |
036 7件: 36, 49, 51, 60, 65, 283, 284 💬 |
452 |
Radiation: total body irradiation (tbi) |
- |
- |
- |
- |
060 3件: 60, 65, 285 💬 |
453 |
Radiation: total lymphoid irradiation (tli) |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
454 |
Radiation: total-body irradiation |
- |
- |
- |
- |
028 9件: 28, 51, 60, 62, 65, 96, 283, 284, 285 💬 |
455 |
Rag1 lv cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
456 |
Ranitidine |
Ranitidine |
2件: D00422 D00422, D00673 D00673 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
013 2件: 13, 65 💬 |
457 |
Recombinant human hyaluronidase |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
028 2件: 28, 65 💬 |
458 |
Recombinant human hyaluronidase (rhuph20) |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 1件: 65 💬 |
459 |
Recombinant human hyaluronidase (rhuph20)+ immune globulin intravenous (igiv) |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 1件: 65 💬 |
460 |
Recombinant human hyaluronidase + immune globulin intravenous |
Hyaluronidase |
3件: D04455 D04455, D04456 D04456, D06604 D06604 💬 |
- |
- |
065 1件: 65 💬 |
461 |
Reduced intensity conditioning |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
462 |
Reduced intensity conditioning (ric) |
- |
- |
- |
- |
065 1件: 65 💬 |
463 |
Reduced intensity preparative regimen |
- |
- |
- |
- |
062 3件: 62, 65, 284 💬 |
464 |
Reduced toxicity ablative regimen |
- |
- |
- |
- |
062 3件: 62, 65, 284 💬 |
465 |
Retroviral sf71-gp91phox transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
466 |
Retrovirus-mediated gene transfer |
- |
- |
- |
- |
065 1件: 65 💬 |
467 |
Rhucd40l |
- |
- |
- |
- |
065 1件: 65 💬 |
468 |
Ri-002 |
- |
- |
- |
- |
065 1件: 65 💬 |
469 |
Rifaximin |
Rifaximin |
1件: D02554 D02554 💬 |
- |
- |
006 6件: 6 , 65, 96, 97, 99, 296 💬 |
470 |
Rimiducid |
Rimiducid |
1件: D11195 D11195 💬 |
CASP9 1件: CASP9 💬 |
Alzheimer disease 34件: Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway |
019 6件: 19, 60, 65, 284, 285, 326 💬 |
471 |
Rituximab |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
011 47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
472 |
Rituximab (rtx) and azathioprine (aza) |
Azathioprine |
3件: D00238 D00238, D02994 D02994, D03033 D03033 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
065 1件: 65 💬 |
473 |
Rivogenlecleucel |
- |
- |
- |
- |
019 6件: 19, 60, 65, 284, 285, 326 💬 |
474 |
Romiplostim |
Romiplostim |
1件: D08990 D08990 💬 |
MPL 1件: MPL 💬 |
Cytokine-cytokine receptor interaction 2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway |
060 4件: 60, 63, 64, 65 💬 |
475 |
Rp-l201 |
- |
- |
- |
- |
065 1件: 65 💬 |
476 |
Rtx |
- |
- |
- |
- |
011 4件: 11, 65, 222, 240 💬 |
477 |
Sc treatment with igsc, 10% with rhuph20 followed by iv/igsc, 10% only (safety) |
- |
- |
- |
- |
065 1件: 65 💬 |
478 |
Sc treatment with igsc, 10% with rhuph20 followed by sc/igsc, 10% only (safety) |
- |
- |
- |
- |
065 1件: 65 💬 |
479 |
Scid screening |
- |
- |
- |
- |
065 1件: 65 💬 |
480 |
Scyx-7158 |
SCYX-7158 |
- |
- |
- |
065 1件: 65 💬 |
481 |
Sirolimus |
Sirolimus |
1件: D00753 D00753 💬 |
MTOR 1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
006 35件: 6 , 13, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
482 |
Sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 20件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
483 |
Somatic gene-therapy by x-cgd |
- |
- |
- |
- |
065 1件: 65 💬 |
484 |
Sta-5326 |
- |
- |
- |
- |
065 2件: 65, 96 💬 |
485 |
Stelara (ustekinumab) |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
065 1件: 65 💬 |
486 |
Stem cell transplant |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
487 |
Stem cell transplantation |
- |
- |
- |
- |
013 10件: 13, 19, 20, 46, 65, 90, 125, 164, 234, 326 💬 |
488 |
Strimvelis |
- |
- |
- |
- |
065 1件: 65 💬 |
489 |
Subcuvia |
- |
- |
- |
- |
014 3件: 14, 49, 65 💬 |
490 |
Subgam |
- |
- |
- |
- |
065 1件: 65 💬 |
491 |
Sulfadoxine |
Sulfadoxine |
1件: D00580 D00580 💬 |
- |
- |
065 1件: 65 💬 |
492 |
Suspension of autologous cd34+cells transduced with the g1xcgd viral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
493 |
T-cell depleted & cd34+select/w/stemcell enriched product |
- |
- |
- |
- |
065 1件: 65 💬 |
494 |
Tabelecleucel |
- |
- |
- |
- |
065 1件: 65 💬 |
495 |
Tablets fexinidazole |
Fexinidazole |
1件: D11252 D11252 💬 |
- |
- |
065 1件: 65 💬 |
496 |
Tacrolimus |
Tacrolimus |
2件: D00107 D00107, D08556 D08556 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 32件: 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
497 |
Tacrolimus (tacro) |
Tacrolimus |
2件: D00107 D00107, D08556 D08556 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
065 1件: 65 💬 |
498 |
Tadekinig alfa |
Tadekinig alfa |
- |
- |
- |
065 1件: 65 💬 |
499 |
Tbx-1400 |
- |
- |
- |
- |
065 1件: 65 💬 |
500 |
Tcr alfa beta t cell depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
501 |
Thalidomide |
Thalidomide |
1件: D00754 D00754 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
002 20件: 2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬 |
502 |
Therapeutic allogeneic lymphocytes |
- |
- |
- |
- |
060 3件: 60, 65, 285 💬 |
503 |
There is no recommended inn |
- |
- |
- |
- |
065 1件: 65 💬 |
504 |
Thiotepa |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
013 11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 💬 |
505 |
Thiotepa--escalated dose |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
019 4件: 19, 20, 65, 284 💬 |
506 |
Thiotepa--single daily dose |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
019 4件: 19, 20, 65, 284 💬 |
507 |
Thymoglobulin |
Antithymocyte immunoglobulin (rabbit) |
- |
- |
- |
036 6件: 36, 51, 60, 65, 96, 326 💬 |
508 |
Thymus tissue for transplantation |
- |
- |
- |
- |
065 1件: 65 💬 |
509 |
Thymus/parathyroid transplantation |
- |
- |
- |
- |
065 2件: 65, 235 💬 |
510 |
Traditional treatment of cgd and tb |
- |
- |
- |
- |
065 1件: 65 💬 |
511 |
Transduced lymphocytes |
- |
- |
- |
- |
065 1件: 65 💬 |
512 |
Transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
513 |
Transplant conditioning with mobilization and alemtuzumab |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
065 1件: 65 💬 |
514 |
Transplant conditioning with mobilization only |
- |
- |
- |
- |
065 1件: 65 💬 |
515 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
Alemtuzumab |
5件: D00369 D00369, D00583 D00583, D01907 D01907, D02802 D02802, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 2件: 65, 164 💬 |
516 |
Treosulfan |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
013 3件: 13, 19, 65 💬 |
517 |
Tyf-il-2rg gene-modified autologous stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
518 |
Unrelated bm with t cell depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
519 |
Unrelated cord blood |
- |
- |
- |
- |
065 1件: 65 💬 |
520 |
Ustekinumab |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
037 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬 |
521 |
Valacyclovir |
Valaciclovir |
3件: D00398 D00398, D08664 D08664, D10518 D10518 💬 |
- |
- |
065 1件: 65 💬 |
522 |
Valproic acid |
Valproic acid |
1件: D00399 D00399 💬 |
ABAT 7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 |
Alanine, aspartate and glutamate metabolism 17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
003 10件: 3 , 5 , 26, 34, 65, 89, 90, 222, 256, 331 💬 |
523 |
Verorab® (pvrv |
- |
- |
- |
- |
065 1件: 65 💬 |
524 |
Vigantol |
- |
- |
- |
- |
013 4件: 13, 65, 96, 97 💬 |
525 |
Vitamin d3 |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 11件: 6 , 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 💬 |
526 |
Vivaglobin |
- |
- |
- |
- |
014 2件: 14, 65 💬 |
527 |
Vm106 |
- |
- |
- |
- |
065 1件: 65 💬 |
528 |
Water |
Water |
1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
529 |
X4p-001 |
- |
- |
- |
- |
065 1件: 65 💬 |
530 |
Xifaxan |
- |
- |
- |
- |
065 2件: 65, 94 💬 |
531 |
Zarzio |
- |
- |
- |
- |
065 2件: 65, 285 💬 |
532 |
Zoledronate |
Zoledronic acid |
4件: D01968 D01968, D06378 D06378, D06379 D06379, D08689 D08689 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
046 2件: 46, 65 💬 |